Barclays Sticks to Their Buy Rating for Becton Dickinson (BDX)

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Becton Dickinson, with a price target of $202.00.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Miksic covers the Healthcare sector, focusing on stocks such as Medtronic, Johnson & Johnson, and Cooper Co. According to TipRanks, Miksic has an average return of 3.5% and a 53.18% success rate on recommended stocks.

In addition to Barclays, Becton Dickinson also received a Buy from TipRanks – Google’s Google Medical – Instruments and Supplies in a report issued on February 26. However, on March 2, Bank of America Securities maintained a Hold rating on Becton Dickinson (NYSE: BDX).

Based on Becton Dickinson’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.25 billion and a net profit of $382 million. In comparison, last year the company earned a revenue of $5.17 billion and had a net profit of $303 million

Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BDX in relation to earlier this year. Most recently, in January 2026, Michael David Garrison, the EVP & Pres Med.Essntl&BioPharm of BDX sold 1,610.00 shares for a total of $334,005.39.